Left Atrial Appendage Market - Forecast(2024 - 2030)

Left Atrial Appendage Market Overview

The Left Atrial Appendage Market size is estimated to reach $2,247 million by 2027. Furthermore, it is poised to grow at a CAGR of 19.7% over the forecast period of 2022-2027. The left arterial appendage is a small ear-shaped sac found in the muscle wall of the left atrium. When a person isn’t suffering from any major ailments, the blood in the left atrium and LAA is squeezed out of the left atrium into the left ventricle (bottom left chamber of the heart) as and when the heart contracts or beat. However, in cases of atrial fibrillation, the electrical impulses which guide the heart to beat do not follow the right motion or order. Thereby, a lot of impulses start through the same time and evenly spread via the atria. Owing to such incoherencies, the blood starts to get collected and thereby start forming clots. Hence, when the clotted blood is pumped out of one’s heart can result in causing a stroke. Oral anticoagulants reduce the chances of strokes. Moreover, LAA closure devices may be recommended to people who are the risk of developing such a condition, some of the popular ones being used in the market is the “Watchman Device.” Further, implantable cardiac devices such as pacemakers and loop recorders are now being used to monitor and help the irregular heartbeat. The rising prevalence of atrial fibrillation and numerous advantages offered by the LAA closure devices are some of the recognized factors driving the Left Atrial Appendage Industry forward in the projected period of 2022-2027.

Report Coverage

The report: “Left Atrial Appendage Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Left Atrial Appendage Market.

By Indication- Paroxysmal, Persistent, Long-Term Persistent, and Permanent Atrial Fibrillation.
By Treatment- Surgical Occlusion, Oral Medication, Loop Recorder, and Others.
By End-Users- Hospitals, Ambulatory Surgical Centers, Private Clinics, Pharmacies, and Others.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

• Geographically, North America’s Left Atrial Appendage market held a dominant market share in the year 2021. It is owing to the presence of robust medical technology companies, CDMOs for medical devices, and even robust support from the federal government to reduce the condition burden. However, Asia-Pacific is expected to offer lucrative growth opportunities to the marketers in the projected period of 2022-2027 owing to a growing medical infrastructure supplemented by the use of AI and ML to substantiate a faster-paced product delivery.
• The rising prevalence of atrial fibrillation and numerous advantages offered by the LAA closure devices are some of the recognized factors driving the Left Atrial Appendage Market. However, owing to the rising medical side-effects post-consumption of oral medication and the high cost of LAA closure devices will and had impeded the market growth.
• A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Left Atrial Appendage Market Report.
  
  

  Left Atrial Appendage Market- Geography (%) for 2021.

  
  

Left Atrial Appendage Market Segmentation Analysis - By Treatment

The left atrial appendage market based on treatment can be further segmented into Surgical Occlusion, Oral Medication, Loop Recorder, and Others. Oral Medication held the largest share in the year 2021. It is predominantly owing to the cost advantage one can reap by following the said line of therapy. Additionally, the therapy treatment is age-old, and most of the population is incapable of taking a surgical occlusion. For example, WARF 2 tablet by Cipla only costs INR 66 for 30 tablets, which roughly translates to INR 2.2 per tablet. Additionally, doctors’ recommendation remains for the patient to consume one pill in a day. Owing to the low-cost implication, the segment held a considerable share.

However, the Surgical Occlusion segment is estimated to be the fastest-growing with a CAGR of 20.5% over the forecast period of 2022-2027. It is owing to the recent advances in the said field of treatment. The results obtained to post such occlusions have been successful and long-lasting. For example, in the clinical trials performed WATCHMAN, a surgical occlusion method showed less procedural complication and higher similar clinical outcomes. Owing to the technical advances, the treatment line would continue to grow.

Left Atrial Appendage Market Segmentation Analysis - By End-Users

The left atrial appendage market based on end-users can be further segmented into Hospitals, Ambulatory Surgical Centers, Private Clinics, Pharmacies, and Others. Pharmacies held the largest market share in the year 2021. It is owing to the wide adoption of anti-coagulants, especially based on the formula of warfarin. Pharmacies conclude both offline and offline, the online sub-sub segment had an edge over the others owing to the easy subscription options which make such regular medicines economically viable. If one opts for a “Care Plan” from TATA 1Mg, then medicines such as Warf-2 can be obtained at INR 65.5, against the MRP of INR 90. 

However, Ambulatory Surgical Centers is estimated to be the fastest-growing, with a CAGR of 20.7% over the forecast period of 2022-2027. It is owing to the surgical occlusion segment growing’s aspect, and the said procedures are generally performed in such Outpatient facilities. Consumer satisfaction, easy medical reimbursement policies, and government support. 

Left Atrial Appendage Market Segmentation Analysis - By Geography

The left atrial appendage market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and Others. North America held a dominant market share of 34% as compared to other regions. It is owing to the predominant presence of major drug manufacturers and their growing inclination for providing R&D budgets to fund new products and services. Additionally, CDMO of medical devices within the US holds a global share of $17.76 billion and holds the equivalent of 33% of the market.

However, Asia-Pacific is estimated to offer lucrative growth opportunities to marketers over the forecast period of 2022-2027. It is owing to the rising use of 5G in healthcare devices and sector, which further leads to the creation of new robust medical devices capable of pre-informing an upcoming stroke or heart attack. Additionally, the regions of India and China are opening their economies for making “medical device outsourcing” an easy job.

Left Atrial Appendage Market Drivers

The rising cases and prevalence of atrial fibrillation supplemented by old age have been a key market driver

AF or AFib has been regarded as the most common heart rhythm abnormality, which has been seen extremely prevalently in the world. 2.2 million Americans, while 4.5 million Europeans are diagnosed with the said condition each year. Additionally, the prevalence is only bound to grow in the times ahead, predominantly owing to the rising geriatric population. With age, the severity and noticeability of rhythmic heart conditions burrow out. As per the Heart Association Journal of 2020, the numbers can grow up to 6-16 million by 2050 in America, while the numbers can range up to 72 million in Asia-Pacific. Owing to the rising geriatric trends across the world, the prevalence of the disease would significantly ramp up.

Numerous advantages offered by technological advancement can be a key market driver

Technological advancements have been a key aspect when talking about the discovery of new and better medical devices. Each year technologies are advanced, which enhances the overall bio-reusability and reduces the cost implication while also reducing the health complication. For example, the WATCHMAN device has been approved by the FDA is for patients who wish to reduce the risk of thromboembolism from the LAA in patients with nonvalvular atrial fibrillation. The device is parachute shaped, which self-expands and closes the LAA. Moreover, people who are wary of the side effects of warfarin can use the said alternative. The device is kept at the opening of LAA and mitigates the chances of releasing clots into the blood. Furthermore, Amplatzer has made devices which is capable of closing holes of the septum within the heart. Owing to such advantages, the market would continue to grow.

Left Atrial Appendage Market Challenges

Disadvantages pertaining to oral medication have hindered treatment and impeded market growth

Blood thinners are the first line of defense for problems pertaining to clots. However, there have been reported problems from the patients, which makes the entire case of oral medications weak. For example, Frequent blood draws have to be made to measure the patient’s international normalized ratio or INR. Additionally, normal patients who are not working on anticoagulants should have an INR below 1.0; however, patients taking the said therapy have their ratios between 2.0 to 3.0. To ascertain such conditions, patients must regularly take tests that can dent significantly on one’s wallet. The device can cost anywhere between $600-$3000, with each strip costing $7 to $18. Lastly, patients have to be mindful about taking vitamin-k owing to the cross-reactivity, and the chances of bleeding increase significantly while taking such medication.

Left Atrial Appendage Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Left Atrial Appendage Market. The top 10- Left Atrial Appendage Market companies are-

1. Boston Scientific Corporation,
2. AtriCure, Inc.,
3. Abbott Laboratories, Inc.,
4. Occlutech,
5. Lifetech Scientific,
6. SentreHEART,
7. Cardia, Inc.,
8. Johnson and Johnson.
9. Coherex
10. Pfizer

Recent Developments

• In November 2021, A clinical trial compared Amulet with a Watchman FLX device for percutaneous left atrial appendage closure. A CCTA or Cardiac Computed Tomography Angiography was conducted after 45 days, which showed that the device achieved a similar rate of occlusion post 45 days. Furthermore, Amulet as compared with Watchman FLX was associated with higher procedural complications but similar clinical outcomes at 45-days. The trial took place for 3 years taking into account 221 various patients, by randomly distributing patients into an equal set of groups.
• In June 2021, Cardiac Insight, a healthcare innovator specializing in wearable cardiac sensor devices announced the 4^th gen of its CARDEA SOLO ECG Monitoring System. The product allows for early detection of cardiac arrhythmias as AIB. The platform enables hospitals and private practice cardiologists and electrophysiologists to eliminate costly ECG report analysis outsourcing and the long wait times to get those reports back. Cardea SOLO facilitates improved patient care and better patient compliance while keeping patient data securely in-house and enhancing overall cybersecurity.
• In August 2020, Boston Scientific launched the latest reiteration of its LAA Ocular device- Watchman FLX. The said uses small spikes which helps in the better anchorage of the device and also prevents embolization. It features a new, fully rounded design that offers physicians the ability to safely enter, and maneuver within, the left atrial appendage. It is the first LAA occluder that can be fully recaptured, repositioned, and redeployed for precise placement.

Relevant Titles